Targeted therapies in colorectal cancer: Complications and management

Current Colorectal Cancer Reports

Volumn 2, Issue 3, 2006, Pages 125-133

  Sundermeyer, Mark L ^b   Lessin, Stuart R ^b   Meropol, Neal J ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 36148962562     PISSN: 15563790     EISSN: 15563804     Source Type: Journal    
DOI: 10.1007/s11888-006-0031-x     Document Type: Review

References (78)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Wells A: EGF receptor. Int J Biochem Cell Biol 1999, 31:637-643.
3. Hackel PO, Zwick E, Prenzel N, Ullrich A: Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr Opin Cell Biol 1999, 11:184-189.
4. Diermeier S, Horvath G, Knuechel-Clarke R, et al.: Epidermal growth factor receptor coexpression modulates susceptibility to herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Exp Cell Res 2005, 304:604-619.
5. Goldstein NS, Armin M: Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 2001, 92:1331-1346.
6. Salomon DS, Brandt R, Ciardiello F, Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995, 19:183-232.
7. Mayer A, Takimoto M, Fritz E, et al.: The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993, 71:2454-2460.
8. Hemming AW, Davis NL, Kluftinger A, et al.: Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67. J Surg Oncol 1992, 51:147-152.
9. Naramura M, Gillies SD, Mendelsohn J, et al.: Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma. Cancer Immunol Immunother 1993, 37:343-349.
10. Saltz L, Rubin M, Hochster H, et al.: Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT- 11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001, 20:3.
11. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al.: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004, 22:1201-1208.
12. Cunningham D, Humblet Y, Siena S, et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan- refractory metastatic colorectal cancer. N Engl J Med 2004, 351:337-345.
13. Lenz HJ, Mayer RJ, Gold PJ, et al.: Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Proc Am Soc Clin Oncol 2004, 22:247.
14. Scott J, Dakhil S, Cosgriff T, et al.: Cetuximab + FOLFOX 6 as first line therapy for metastatic colorectal cancer. Proc Am Soc Clin Oncol 2005, 23:3705.
15. Saltz LB, Lenz H, Kindler H, et al.: Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Proc Am Soc Clin Oncol 2005, 23:248s.
16. Comparison of combination chemotherapy regimens with or without cetuximab in treating patients who have undergone surgery for stage III colon cancer. Available at http://www.cancer.gov. Accessed January 19, 2006.
17. Malik I, Hecht JR, Patnaik A, et al.: Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2005, 23:251.
18. Cheifetz A, Mayer L: Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med 2005, 72:250-256.
19. Erbitux [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2004. Available at www.erbitux.com.
20. Jost M, Kari C, Rodeck U: The EGF receptor-an essential regulator of multiple epidermal functions. Eur J Dermatol 2000, 10:505-510.
21. Segaert S, Van Cutsem E: Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005, 16:1425-1433.
22. Busam KJ, Capodieci P, Motzer R, et al.: Cutaneous sideeffects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001, 144:1169-1176.
23. Mascia F, Mariani V, Girolomoni G, Pastore S: Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol 2003, 163:303-312.
24. Micantonio T, Fargnoli MC, Ricevuto E, et al.: Efficacy of treatment with tetracyclines to prevent acneiform eruption secondary to cetuximab therapy. Arch Dermatol 2005, 141:1173-1174.
25. Gutzmer R, Werfel T, Mao R, et al.: Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy. Br J Dermatol 2005, 153:849-851.
26. Sapadin AN, Fleischmajer R: Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006, 54:258-265.
27. Schrag D, Chung KY, Flombaum C, Saltz L: Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst 2005, 97:1221-1224.
28. Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
29. Giantonio BJ, Catalano PJ, Meropol NJ, et al.: High-dose bevacizumab improves survival when combined with FOLFOX4 in patients with previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) Study E3200. Proc Am Soc Clin Oncol 2005, 23:1.
30. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100:57-70.
31. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
32. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990, 82:4-6.
33. Bergers G, Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003, 3:401-410.
34. Longo R, Sarmiento R, Fanelli M, et al.: Anti-angiogenic therapy: rationale, challenges and clinical studies. Angiogenesis 2002, 5:237-256.
35. Dor Y, Porat R, Keshet E: Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. Am J Physiol Cell Physiol 2001, 280: C1367-1374.
36. Acker T, Plate KH: Hypoxia and hypoxia inducible factors (HIF) as important regulators of tumor physiology. Cancer Treat Res 2004, 117:219-248.
37. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
38. Tischer E, Mitchell R, Hartman T, et al.: The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991, 266:11947-11954.
39. Shibuya M, Yamaguchi S, Yamane A, et al.: Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 1990, 5:519-524.
40. Terman BI, Dougher-Vermazen M, Carrion ME, et al.: Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992, 187:1579-1586.
41. Matthews W, Jordan CT, Gavin M, et al.: A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. Proc Natl Acad Sci U S A 1991, 88:9026-9030.
42. Pajusola K, Aprelikova O, Armstrong E, et al.: Two human FLT4 receptor tyrosine kinase isoforms with distinct carboxy terminal tails are produced by alternative processing of primary transcripts. Oncogene 1993, 8:2931-2937.
43. Galland F, Karamysheva A, Pebusque MJ, et al.: The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor. Oncogene 1993, 8:1233-1240.
44. Hiratsuka S, Maru Y, Okada A, et al.: Involvement of flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis. Cancer Res 2001, 61:1207-1213.
45. Dvorak HF: Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002, 20:4368-4380.
46. Zeng H, Dvorak HF, Mukhopadhyay D: Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) peceptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinasedependent pathways. J Biol Chem 2001, 276:26969-26979.
47. Valtola R, Salven P, Heikkila P, et al.: VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 1999, 154:1381-1390.
48. Kitsukawa T, Shimono A, Kawakami A, et al.: Overexpression of a membrane protein, neuropilin, in chimeric mice causes anomalies in the cardiovascular system, nervous system and limbs. Development 1995, 121:4309-4318.
49. Takashima S, Kitakaze M, Asakura M, et al.: Targeting of both mouse neuropilin-1 and neuropilin-2 genes severely impairs developmental yolk sac and embryonic angiogenesis. Proc Natl Acad Sci U S A 2002, 99:3657-3662.
50. Alon T, Hemo I, Itin A, et al.: Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995, 1:1024-1028.
51. Zachary I, Gliki G: Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res 2001, 49:568-581.
52. Meadows KN, Bryant P, Pumiglia K: Vascular endothelial growth factor induction of the angiogenic phenotype requires Ras activation. J Biol Chem 2001, 276:49289-49298.
53. Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 1997, 18:4-25.
54. Zachary I: Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol 2001, 280:C1375-1386.
55. Dvorak HF, Brown LF, Detmar M, Dvorak AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995, 146:1029-1039.
56. Kim KJ, Li B, Winer J, et al.: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362:841-844.
57. Margolin K, Gordon MS, Holmgren E, et al.: Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 2001, 19:851-856.
58. Gordon MS, Margolin K, Talpaz M, et al.: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001, 19:843-850.
59. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al.: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003, 21:60-65.
60. Skillings JR, Johnson DH, Miller K, et al.: Arterial thromboembolic events in a pooled analysis of 5 randomized, controlled trials of bevacizumab with chemotherapy. J Clin Oncol 2005, 23:3019.
61. Kabbinavar FF, Schulz J, McCleod M, et al.: Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005, 23:3697-3705.
62. Kabbinavar FF, Hambleton J, Mass RD, et al.: Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005, 23:3706-3712.
63. Chobanian AV, Bakris GL, Black HR, et al.: The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
64. Avastin [package insert]. San Francisco, CA: Genentech; 2004. Available at www.avastin.com.
65. Ziche M, Morbidelli L, Choudhuri R, et al.: Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor- induced angiogenesis. J Clin Invest 1997, 99:2625-2634.
66. Sane DC, Anton L, Brosnihan KB: Angiogenic growth factors and hypertension. Angiogenesis 2004, 7:193-201.
67. Felmeden DC, Spencer CG, Belgore FM, et al.: Endothelial damage and angiogenesis in hypertensive patients: relationship to cardiovascular risk factors and risk factor management. Am J Hypertens 2003, 16:11-20.
68. Eremina V, Quaggin SE: The role of VEGF-A in glomerular development and function. Curr Opin Nephrol Hypertens 2004, 13:9-15.
69. Ostendorf T, Kunter U, Eitner F, et al.: VEGF(165) mediates glomerular endothelial repair. J Clin Invest 1999, 104:913-923.
70. Bloch W, Huggel K, Sasaki T, et al.: The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing. Faseb J 2000, 14:2373-2376.
71. Klein SA, Bond SJ, Gupta SC, et al.: Angiogenesis inhibitor TNP-470 inhibits murine cutaneous wound healing. J Surg Res 1999, 82:268-274.
72. Streit M, Velasco P, Riccardi L, et al.: Thrombospondin- 1 suppresses wound healing and granulation tissue formation in the skin of transgenic mice. Embo J 2000, 19:3272-3282.
73. Johnson DH, Fehrenbacher L, Novotny WF, et al.: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004, 22:2184-2191.
74. Yang JC, Haworth L, Sherry RM, et al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349:427-434.
75. Miller KD, Wang M, Gralow J, et al.: A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer. In the Proceedings of the American Society of Clinical Oncology. Orlando, FL; May 13-17, 2005.
76. Scappaticci FA, Fehrenbacher L, Cartwright T, et al.: Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005, 91:173-180.
77. Ellis LM, Curley SA, Grothey A: Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol 2005, 23:4853-4855.
78. Kilickap S, Abali H, Celik I: Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol 2003, 21:3542,author reply 3.